BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage...
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into the commercial phase of its...
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is approaching a defining clinical milestone as it...
Drug repurposing model reduces risk and capital required Working to develop Ifenprodil for...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Steve Darling from Proactive to discuss positive results from the company's 60-patient Phase 2 clinical trial of bezisterim in Parkinson's disease, which demonstrated statistically significant improvements over placebo in both motor and...
